title: Effectiveness of 0.1% topical tacrolimus in adult and children patients with vitiligo.
abstract: Topical corticosteroids and phototherapy are the conventional treatments of vitiligo. However, the acrofacial and segmental types are often unresponsive to these treatments. Nowadays, a few studies have been conducted on efficacy of topical tacrolimus in treatment of vitiligo including vulgaris and segmental types. Nevertheless, the acrofacial type has never been investigated with this topical therapy. The aim of our study is to evaluate the effectiveness of 0.1% tacrolimus ointment in patients including all types of vitiligo. Forty-two patients with vitiligo (22 adults, 20 children) were enrolled in this study. They were treated with 0.1% tacrolimus ointment twice daily for 6 months. Of these 42 patients, 38 of them completed the treatment process. The mean age of the patients was 27.8 years. The response rate was 76.09%. The vulgaris and focalis had a maximum response rate of 94.12%. The response rates for segmentalis and acrofacialis were 76.92% and 56.25% respectively. Concerning the response, age groups, types and location of vitiligo, there was significant difference in all variables (P = 0.001, P = 0.001, P = 0.025, respectively). Children had approximately nine times higher odds (95% CI = 1.09, 81.88) of having better response to the treatment than adults. The disease duration of 5 years or less also showed a better response. In conclusion, topical tacrolimus can be used for the treatment of patients with vitiligo. We recommend that, other than in the vulgaris type, topical tacrolimus may be considered as a treatment for two difficult to treat types of vitiligo, acrofacialis and segmentalis, before considering other modalities.
authors.affiliation: Faculty of Medicine, Skin Center, Srinakharinwirot University, Bangkok, Thailand. umontree@yahoo.com
authors.forename: Montree
authors.initials: M
authors.lastname: Udompataikul
authors.forename: Pairutch
authors.initials: P
authors.lastname: Boonsupthip
authors.forename: Rungthiwa
authors.initials: R
authors.lastname: Siriwattanagate
mesh_terms: D000279:Administration, Cutaneous; D000328:Adult; D002648:Child; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D008297:Male; D016559:Tacrolimus / Q000008:administration & dosage*; D016896:Treatment Outcome; D014820:Vitiligo / Q000188:drug therapy*
chemical_list: D007166:Immunosuppressive Agents; D016559:Tacrolimus